```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS  4  OCT 28   KOREAPAT now available on STN
 NEWS  5  NOV 30   PHAR reloaded with additional data
 NEWS  6  DEC 01   LISA now available on STN
 NEWS  7  DEC 09   12 databases to be removed from STN on December 31, 2004
 NEWS  8  DEC 15   MEDLINE update schedule for December 2004
 NEWS  9  DEC 17   ELCOM reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  10 DEC 17   COMPUAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  11 DEC 17   SOLIDSTATE reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  12 DEC 17   CERAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  13 DEC 17   THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS  14 DEC 30   EPFULL: New patent full text database to be available on STN
 NEWS  15 DEC 30   CAPLUS - PATENT COVERAGE EXPANDED
 NEWS  16 JAN 03   No connect-hour charges in EPFULL during January and
                   February 2005
 NEWS  17 JAN 11   CA/CAPLUS - Expanded patent coverage to include Russia
                   (Federal Institute of Industrial Property)

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *


*GENBANK      - Genetic Sequence Data Bank
```

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 11:14:35 ON 14 JAN 2005

=> file medline, uspatful, dgene, embase, wpids
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 11:14:57 ON 14 JAN 2005

FILE 'USPATFULL' ENTERED AT 11:14:57 ON 14 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:14:57 ON 14 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 11:14:57 ON 14 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:14:57 ON 14 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s GFP fusion protein
L1 1736 GFP FUSION PROTEIN

=> s l1 and soluble domain
L2 0 L1 AND SOLUBLE DOMAIN

=> s soluble protein domain
L3 78 SOLUBLE PROTEIN DOMAIN

=> s l3 and l1
L4 1 L3 AND L1

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN
TI Methods for producing protein domains and analyzing three dimensional structures of proteins by using said domains
AB There is provided a method for producing a **soluble protein domain** comprising: (a) preparing two or more DNA fragments by partially digesting a DNA coding for a protein; (b) expressing the protein which is coded on each of said DNA fragments, as a fusion protein with a functional protein; (c) selecting the fusion protein exhibiting said function among two or more fusion proteins synthesized in step (b); and, (d) synthesizing the **soluble protein domain** which is coded on said DNA fragment in a cell-free system, wherein said **soluble protein domain** is included in said fusion protein selected in step (c). By using this method, it can be easy and efficient to analyze the three dimensional structure of proteins of many clones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:258817 USPATFULL
TITLE: Methods for producing protein domains and analyzing three dimensional structures of proteins by using said domains
INVENTOR(S): Seki, Eiko, Kanagawa, JAPAN
Kigawa, Takanori, Kanagawa, JAPAN
Yokoyama, Shigeyuki, Kanagawa, JAPAN

NUMBER KIND DATE

```
                        ---------------- ------ --------
PATENT INFORMATION:     US 2002142387      A1   20021003
APPLICATION INFO.:      US 2001-994573     A1   20011126  (9)

                               NUMBER         DATE
                        ---------------- --------
PRIORITY INFORMATION:   JP 2001-62703      20010306
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE,
                        SUITE 500, SAN DIEGO, CA, 92130-2332
NUMBER OF CLAIMS:       14
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     5 Drawing Page(s)
LINE COUNT:             617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> e Seki/au
E1            2     SEKHUJA V/AU
E2            1     SEKHWELA MOGODISHENG/AU
E3            3 --> SEKI/AU
E4          474     SEKI A/AU
E5           21     SEKI AKIHIKO/AU
E6            7     SEKI AKIHIRO/AU
E7            1     SEKI AKIKAZU/AU
E8            3     SEKI AKIKO/AU
E9            4     SEKI AKINOBU/AU
E10          11     SEKI AKINORI/AU
E11           7     SEKI AKIRA/AU
E12           1     SEKI AKITERU/AU

=> s e3
L5            3 SEKI/AU

=> d l5 ti abs ibibi tot
'IBIBI' IS NOT A VALID FORMAT FOR FILE 'WPIDS'

The following are valid formats:

TRI   SAM   Short Information (Syn.: TRIAL,SAMPLE)
STR         DERWENT Chemical Resource Structure
HITSTR      HITSTRUCTURES
BIB         Bibliographic Data
BRIEFG.H    Brief Contents of Document with GI.H
BRIEFG      Brief Contents of Document with GI
BRIEF       Brief Contents of Document
IBRIEFG.H   Brief Contents of Document with GI.H, Indented Version
IBRIEFG     Brief Contents of Document with GI, Indented Version
IBRIEF      Brief Contents of Document, Indented Version
MAXG        All Data with GIS and GI.H
MAX         All Data
ALLG.H      All Data Except ABEQ, CMC, and PLC with GI.H
ALLG        All Data Except ABEQ, CMC, and PLC with GI
ALL         All Data Except ABEQ, CMC, and PLC
FULL        All Data Except ABEQ, CMC, and PLC plus TECH and PRIO
FULLG       All Data Except ABEQ, CMC, and PLC with GI plus TECH and PRIO
DALL        Delimited ALL Format
BASIC       Basic Patent Information
STD         Default
IDE         Structure File Default
IALLG.H     Indented Version of ALL Format with GI.H
IALLG       Indented Version of ALL Format with GI
IALL        Indented Version of ALL Format
```

IFULL		Indented Version of FULL Format
IFULLG		Indented Version of FULLG Format
ISTD		Indented Version of STD Format
IBIB		Indented Version of BIB Format
ABS		All Abstracts
CODE	IND	Manual-, Plasdoc-, and Chemical Code plus Keywords
SUM		Title and Novelty

AB		Abstract (Basic)
ABEQ		Abstract, Equivalent
ADT		Application Details
ADT.B		Application Details Basic
AI	AP	Application Information
AI.B		Application Information Basic
AN		Accession Number
AN.S		DERWENT Chemistry Resource Accession Number, DCR Segment
APPS		Application Number Group
AW		Additional Words
CC		Classification Code (Substance Descriptor
CMC		Chemical Code
CMT		Comment
CN		Chemical Name
CN.P		Chemical Name Preferred
CN.S		Systematic Chemical Name
CR	XR	Cross Reference
CYC		Country Count
DAN		DERWENT Accession Number List
DC		DERWENT Class
DCN		DERWENT Compound Number
DCR		DERWENT Chemistry Resource Accession Number
DCRE		DERWENT Chemistry Resource Number
DCSE		DERWENT Chemistry Resource Number, DCR Segment
DN		Document Number CPI and Non CPI
DNC		Document Number CPI
DNN		Document Number Non CPI
DRN		DERWENT Registry Number
DS		Designated States
ED		Entry Date
EDCR		Entry Date DERWENT Chemistry Resource
FA		Field Availability
FAS		Field Availability Supplementary Data
FAM		Patent Family
FDT		Filing Details
FG	AM	Fragment Code
FS		File Segment
IC		International Patent Classification
GI		Graphical Information
GI.H		Graphical Information, High Resolution
GIS		Graphical Information Size
ICA		IPC, Additional (Supplementary)
ICI		IPC, Index (Complementary)
ICM		IPC, Main
ICS		IPC, Secondary
IN	AU	Inventor
IPC		International Patent Classification
KS		Plasdoc Key Serials
KW		Keyword Indexing, Including DERWENT Chemistry Resource Numbers, DWPI Segment
M0		Chemical Code (Pre 1970)
M1-6		Chemical Codes
MC		Manual Code
MF		Molecular Formula
MW		Molecular Weight

```
NOV          Novelty
PA     CS    Patent Assignee
PATS         Patent Number Group
PI     PN    Patent Information
PI.B   PN.B  Patent Information Basic
PIA          Patent Information Abbreviated
PIA.B        Patent Information Abbreviated Basic
PLC          Plasdoc Codes
PLE          Enhanced Plasdoc Codes
PNC          Patent Number Count
PRAI   PRN   Priority Information
PRIO         Prior Art
REP  RPN RE  Reference Patent Information
RIN          Ring Index Number
SDCN         Structure Segment DERWENT Compound Number
SDRN         Structure Segment DERWENT Registry Number
SMF          Standardized Molecular Formula
SRIN         Structure Segment Ring Index Number
SY           Synonym Name
TECH         Technology Focus
TI           Title
TT           Title Terms
UP           Update Date
UPA          Update Date Plasdoc Code
UPAB         Update Date Abstract
UPB          Update Date Chemical Code
UPCR         Update Date DERWENT Chemistry Resource
UPKW         Update Date Keyword Indexing
UPP          Update Date Patent
UPS          Update Date SDI
UPTX         Update New Content Abstract Fields
UPWX         Update Date WPI Cross Reference
ENTER DISPLAY FORMAT (STD):d his
'D' IS NOT A VALID FORMAT FOR FILE 'WPIDS'
'HIS' IS NOT A VALID FORMAT FOR FILE 'WPIDS'

The following are valid formats:

TRI   SAM    Short Information (Syn.: TRIAL,SAMPLE)
STR          DERWENT Chemical Resource Structure
HITSTR       HITSTRUCTURES
BIB          Bibliographic Data
BRIEFG.H     Brief Contents of Document with GI.H
BRIEFG       Brief Contents of Document with GI
BRIEF        Brief Contents of Document
IBRIEFG.H    Brief Contents of Document with GI.H, Indented Version
IBRIEFG      Brief Contents of Document with GI, Indented Version
IBRIEF       Brief Contents of Document, Indented Version
MAXG         All Data with GIS and GI.H
MAX          All Data
ALLG.H       All Data Except ABEQ, CMC, and PLC with GI.H
ALLG         All Data Except ABEQ, CMC, and PLC with GI
ALL          All Data Except ABEQ, CMC, and PLC
FULL         All Data Except ABEQ, CMC, and PLC plus TECH and PRIO
FULLG        All Data Except ABEQ, CMC, and PLC with GI plus TECH and PRIO
DALL         Delimited ALL Format
BASIC        Basic Patent Information
STD          Default
IDE          Structure File Default
IALLG.H      Indented Version of ALL Format with GI.H
IALLG        Indented Version of ALL Format with GI
IALL         Indented Version of ALL Format
IFULL        Indented Version of FULL Format
IFULLG       Indented Version of FULLG Format
```

ISTD		Indented Version of STD Format
IBIB		Indented Version of BIB Format
ABS		All Abstracts
CODE	IND	Manual-, Plasdoc-, and Chemical Code plus Keywords
SUM		Title and Novelty

AB		Abstract (Basic)
ABEQ		Abstract, Equivalent
ADT		Application Details
ADT.B		Application Details Basic
AI	AP	Application Information
AI.B		Application Information Basic
AN		Accession Number
AN.S		DERWENT Chemistry Resource Accession Number, DCR Segment
APPS		Application Number Group
AW		Additional Words
CC		Classification Code (Substance Descriptor
CMC		Chemical Code
CMT		Comment
CN		Chemical Name
CN.P		Chemical Name Preferred
CN.S		Systematic Chemical Name
CR	XR	Cross Reference
CYC		Country Count
DAN		DERWENT Accession Number List
DC		DERWENT Class
DCN		DERWENT Compound Number
DCR		DERWENT Chemistry Resource Accession Number
DCRE		DERWENT Chemistry Resource Number
DCSE		DERWENT Chemistry Resource Number, DCR Segment
DN		Document Number CPI and Non CPI
DNC		Document Number CPI
DNN		Document Number Non CPI
DRN		DERWENT Registry Number
DS		Designated States
ED		Entry Date
EDCR		Entry Date DERWENT Chemistry Resource
FA		Field Availability
FAS		Field Availability Supplementary Data
FAM		Patent Family
FDT		Filing Details
FG	AM	Fragment Code
FS		File Segment
IC		International Patent Classification
GI		Graphical Information
GI.H		Graphical Information, High Resolution
GIS		Graphical Information Size
ICA		IPC, Additional (Supplementary)
ICI		IPC, Index (Complementary)
ICM		IPC, Main
ICS		IPC, Secondary
IN	AU	Inventor
IPC		International Patent Classification
KS		Plasdoc Key Serials
KW		Keyword Indexing, Including DERWENT Chemistry Resource Numbers, DWPI Segment
M0		Chemical Code (Pre 1970)
M1-6		Chemical Codes
MC		Manual Code
MF		Molecular Formula
MW		Molecular Weight
NOV		Novelty
PA	CS	Patent Assignee

```
PATS          Patent Number Group
PI     PN     Patent Information
PI.B   PN.B   Patent Information Basic
PIA           Patent Information Abbreviated
PIA.B         Patent Information Abbreviated Basic
PLC           Plasdoc Codes
PLE           Enhanced Plasdoc Codes
PNC           Patent Number Count
PRAI   PRN    Priority Information
PRIO          Prior Art
REP    RPN RE Reference Patent Information
RIN           Ring Index Number
SDCN          Structure Segment DERWENT Compound Number
SDRN          Structure Segment DERWENT Registry Number
SMF           Standardized Molecular Formula
SRIN          Structure Segment Ring Index Number
SY            Synonym Name
TECH          Technology Focus
TI            Title
TT            Title Terms
UP            Update Date
UPA           Update Date Plasdoc Code
UPAB          Update Date Abstract
UPB           Update Date Chemical Code
UPCR          Update Date DERWENT Chemistry Resource
UPKW          Update Date Keyword Indexing
UPP           Update Date Patent
UPS           Update Date SDI
UPTX          Update New Content Abstract Fields
UPWX          Update Date WPI Cross Reference
ENTER DISPLAY FORMAT (STD):end

=> d his

     (FILE 'HOME' ENTERED AT 11:14:35 ON 14 JAN 2005)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 11:14:57 ON 14
     JAN 2005
L1          1736 S GFP FUSION PROTEIN
L2             0 S L1 AND SOLUBLE DOMAIN
L3            78 S SOLUBLE  PROTEIN DOMAIN
L4             1 S L3 AND L1
                 E SEKI/AU
L5             3 S E3

=> d l5 ti abs ibib tot

L5   ANSWER 1 OF 3  WPIDS  COPYRIGHT 2005 THE THOMSON CORP on STN
TI   New 2-halo-oxetanocin A derivs. - used as antiviral agents for treating
     HIV, cytomegalovirus etc..
AN   1992-227355 [28]   WPIDS
AB   EP    493722 A UPAB: 19931006
     2-Halo-oxetanocin A and its 4'-phosphate of formula (I) are new. X =
     halogen; and R = H or a phosphoric acid residue of formula (i) Also new
     are 2-halo-oxetanocin A derivs. of formula (I). Each R1 independently = H,
     acyl or tri(1-10C hydrocarbon)-silyl gp., provided that both R1 are not H
     simultaneously.
          USE/ADVANTAGE - (I) have antiviral activity against DNA virus and RNA
     virus and are useful as antiviral agents, partic. against HIV, adenovirus,
     parvovirus, papovavirus, pox virus, herpes virus, cytomegalovirus,
     hepatitis B virus, togavirus and arenavirus. (I) are not inactivated by
     adensine deaminase, found extensively in living bodies, so they exhibit a
     high residual activity The daily dosage of (I) is about 1-300mg/kg in
     non-oral admin. and 5-500mg/kg in oral admin. (I) have low toxicity.
```

Anti-cytomegalovirus activity was measured by infecting human embryo fibroblast with plaque forming units of cytomegalovirus (A0169) strain). After 1 hr. it was covered with a layer of medium containing varied concns. of test cpd. the mixture was cultured for 10 days at 37 deg. C in a 5% v/v CO2 incubator, then the number of plaques formed was measured. ED50 values were, for 2-fluoro-oxetanocin A (1) 0.3 micro-g/ml, and for oxetanocin A 13.0 micro-g/ml.

0/0

ABEQ US 5283331 A UPAB: 19940322

2-halogeno-oxetanocin A derivs. of formula (I) and (II) are new. In the formula X=F or Cl, R = H or phosphoric acid residue; and R1 = H, acyl gp. or a tri(1-10C hydrocarbon)-silyl gp. provided that both R1 gps. are not H.

USE/ADVANTAGE - As active ingredient in therapeutic drug for viral diseases. The cpds. are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity.

Dwg.0/0

ACCESSION NUMBER: 1992-227355 [28] WPIDS
DOC. NO. CPI: C1992-102709
TITLE: New 2-halo-oxetanocin A derivs. - used as antiviral agents for treating HIV, cytomegalovirus etc..
DERWENT CLASS: B02
INVENTOR(S): HOSHINO, H; KITAGAWA, M; MASUDA, A; NISHIYAMA, Y; SAITO, S; SEKI, J; SHIMADA, N; SEKI, J I; **SEKI**
PATENT ASSIGNEE(S): (NIPK) NIPPON KAYAKU KK
COUNTRY COUNT: 12
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 493722	A1	19920708	(199228)*	EN	20
R: CH DE ES FR GB IT LI NL SE					
JP 05032691	A	19930209	(199311)		11
CA 2057432	A	19920621	(199319)		
US 5283331	A	19940201	(199406)		10

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 493722	A1	EP 1991-121327	19911212
JP 05032691	A	JP 1991-352945	19911217
CA 2057432	A	CA 1991-2057432	19911211
US 5283331	A	US 1991-804773	19911209

PRIORITY APPLN. INFO: JP 1990-411947 19901220; JP 1991-57754 19910301; JP 1990-57754 19910301

L5 ANSWER 2 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

TI Initialising circuit for semiconductor device - prevents malfunction onrestart by using transistor circuit which only outputs high or low potentiallevels.

AN 1992-097095 [12] WPIDS

AB WO 9203825 A UPAB: 19931006

The initialising circuit (20) is provided with a sensing circuit (TR1, TR2, R, 21) which operates according to switching on the power supply and senses that the power supply voltage (Vcc) increases to a predetermined voltage. The initialising circuit also has a circuit (22) for controlling output levels which responds to a sense signal (V1) outputted from the sensing circuit and pulls up the level of the output signal (Vout) of the initialising circuit to a high potential level or pulls it down to a low potential level.

After the power is interrupted and when the power is supplied again, the latching circuit (30) is fed with the output signal controlled by the circuit (22) as its power source voltage. Consequently the latching circuit can be reliably initialised.

6/9

ABEQ US 5307319 A UPAB: 19940608

The initialization setting circuit (20) adapted to set an initial condition of a latch circuit in a semiconductor device upon ON-set of the power supply, includes a detecting circuit (TR1, TR2, R, 21) responsive to ON-set of power supply to detect the power source voltage (Vcc) reaching a given voltage. An output level control circuit (22) responds to the detecting signal output from the detecting circuit, for elevating up the level of an output signal of the initialization setting circuit to a high potential level or lowering the level of the output signal of the initialization setting circuit to a low potential level.

By supplying the output signal controlled by the output level control circuit of the latch circuit as the power source voltage, the operation of the latch circuit is synchronized when the power source voltage is shut down.

ADVANTAGE - Malfunction can be successfully prevented upon resetting of power supply.

Dwg.1/9

ACCESSION NUMBER: 1992-097095 [12] WPIDS
DOC. NO. NON-CPI: N1992-072587
TITLE: Initialising circuit for semiconductor device - prevents malfunction onrestart by using transistor circuit which only outputs high or low potentiallevels.
DERWENT CLASS: R35 U14
INVENTOR(S): KOUKETSU, T; SEKI, T; KOHKETSU, T; **SEKI**
PATENT ASSIGNEE(S): (FUIT) FUJITSU LTD; (FUIV) FUJITSU VLSI LTD
COUNTRY COUNT: 6
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9203825	A	19920305	(199212)*		30
RW: DE GB					
W: KR US					
JP 04106784	A	19920408	(199221)		5
EP 500958	A1	19920902	(199236)	EN	17
R: DE FR GB					
US 5307319	A	19940426	(199416)		14
EP 500958	A4	19930407	(199526)		
KR 9510566	B1	19950919	(199847)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9203825	A	WO 1991-JP1143	19910828
JP 04106784	A	JP 1990-227215	19900828
EP 500958	A1	EP 1991-915718	19910828
		WO 1991-JP1143	19910828
US 5307319	A	WO 1991-JP1143	19910828
		US 1992-844659	19920402
EP 500958	A4	EP 1991-915718	
KR 9510566	B1	WO 1991-JP1143	19910828
		KR 1992-700991	19920428

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 500958	A1 Based on	WO 9203825

US 5307319 A Based on WO 9203825

PRIORITY APPLN. INFO: JP 1990-227215 19900828

L5 ANSWER 3 OF 3 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI New antiviral and carcinostatic nucleic acid derivs. - especially 9-((C1R,2R,3S)-2,3-bis (hydroxymethyl)-1-cyclopentyl) adenine, useful against herpes viruses and carcinostatic agents.
AN 1992-034124 [05] WPIDS
AB EP 468352 A UPAB: 19931119
Nucleic acid derivs. of formula (I) and their salts are new. In (I) B = nucleic acid base derivative; A1,A2 = OR1 or OCOR1; R1 = H, opt. substd. alkyl or opt. substd. aryl; l = 0 or 1; m,n = 0-2; provided that when l and m are 0, n is 0 or 2.

Pref. base derivs. represented by B include purine and pyrimidine bases opt. protected. Examples include the following: (II), (III), (IV) or (V). In the formulae, Y = H, NH2 or halo; R5 = alkyl opt. susbtd.; R6 = H, alkyl, benzyl, opt. halo substd. vinyl or halo.

USE - Cpds. (I) are antiviral agents useful against herpes viruses, varicella zoster virus, cytomegalo virus, Epstein-Barr virus and many other viral diseases including hepatitis B and C, AIDS, ATL and the like. They are also expected to be useful as a carcinostatic agent. Dosage is 1-500 mg/kg/day. @(25pp Dwg.No.0/0)
0/0
ABEQ US 5374625 A UPAB: 19950207
9-(2,3-bis (hydroxymethyl) -1-cyclopentyl)adenine, 9-(3,4-bis)hydroxymethyl)- 1-cyclohexyl)adenine or guanidine and their salts are new.

USE - (I) have antiviral activity and are active against herpes labialis, genitalis and zoster infections of HSV I and II. Varicella-Zoster virus; cytomegalovirus and Epstein-Barr virus at the time of immunodepression, and many other viral diseases such as viral hepatitises caused by hepatitis B or C, viral diseases of respiratory organs or digestive organs, AIDS and ATL and are also expected to be useful as carcinostatic agents. Admin is oral, I.V or SC at does of 1-500 mg/kg/day.
Dwg.0/0
ACCESSION NUMBER: 1992-034124 [05] WPIDS
TITLE: New antiviral and carcinostatic nucleic acid derivs. - especially 9-((C1R,2R,3S)-2,3-bis (hydroxymethyl)-1-cyclopentyl) adenine, useful against herpes viruses and carcinostatic agents.
DERWENT CLASS: B02 B03
INVENTOR(S): AKABA, H; HOSHINO, H; ICHIKAWA, Y; MATSUBARA, K; NAGAHATA, T; SEKI, J; SHIOZAWA, A; SUGAWARA, Y; AKABA, K; **SEKI**
PATENT ASSIGNEE(S): (NIPK) NIPPON KAYAKU KK
COUNTRY COUNT: 13
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 468352	A	19920129	(199205)*		
R: CH DE ES FR GB IT LI					
AU 9181253	A	19920130	(199215)		
CA 2047644	A	19920125	(199215)		
CN 1059524	A	19920318	(199244)		
JP 05001044	A	19930108	(199306)		16
EP 468352	A3	19920715	(199334)		
AU 642031	B	19931007	(199346)		
US 5374625	A	19941220	(199505)		13

APPLICATION DETAILS:

```
     PATENT NO       KIND                  APPLICATION          DATE
     ------------------------------------------------------------------
     EP 468352       A                     EP 1991-111925       19910717
     CN 1059524      A                     CN 1991-105789       19910724
     JP 05001044     A                     JP 1991-203604       19910719
     EP 468352       A3                    EP 1991-111925       19910717
     AU 642031       B                     AU 1991-81253        19910722
     US 5374625      A                     US 1991-731459       19910717

FILING DETAILS:

     PATENT NO       KIND                    PATENT NO
     ------------------------------------------------
     AU 642031       B  Previous Publ.   AU 9181253

PRIORITY APPLN. INFO: JP 1990-193957       19900724


=> d his

     (FILE 'HOME' ENTERED AT 11:14:35 ON 14 JAN 2005)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 11:14:57 ON 14
     JAN 2005
L1          1736 S GFP FUSION PROTEIN
L2             0 S L1 AND SOLUBLE DOMAIN
L3            78 S SOLUBLE  PROTEIN DOMAIN
L4             1 S L3 AND L1
                 E SEKI/AU
L5             3 S E3

=> s l1 and l5
L6             0 L1 AND L5

=> e Kigawa/au
E1             1     KIGATA TETSUYUKI/AU
E2             1     KIGAW A/AU
E3             0 --> KIGAWA/AU
E4            11     KIGAWA A/AU
E5             1     KIGAWA AKIHIKO/AU
E6             4     KIGAWA AKIHIRO/AU
E7            11     KIGAWA G/AU
E8            21     KIGAWA H/AU
E9             1     KIGAWA H H/AU
E10            1     KIGAWA HIROMITSU/AU
E11            4     KIGAWA HIROSHI/AU
E12            3     KIGAWA HITOSHI/AU

=> s e4
L7            11 "KIGAWA A"/AU

=> s l7 and l11
L11 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l7 and l1
L8             0 L7 AND L1
```